Once-weekly (70 mg/m2) vs twice-weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., and CHAMPION-1 trials

  1. Moreau, P.
  2. Stewart, K.A.
  3. Dimopoulos, M.
  4. Siegel, D.
  5. Facon, T.
  6. Berenson, J.
  7. Raje, N.
  8. Berdeja, J.G.
  9. Orlowski, R.Z.
  10. Yang, H.
  11. Ma, H.
  12. Klippel, Z.
  13. Zahlten-Kumeli, A.
  14. Mezzi, K.
  15. Iskander, K.
  16. Mateos, M.-V.
Journal:
Cancer Medicine

ISSN: 2045-7634

Year of publication: 2020

Volume: 9

Issue: 9

Pages: 2989-2996

Type: Article

DOI: 10.1002/CAM4.2945 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals